Christine Ring - Sep 10, 2021 Form 4 Insider Report for Nurix Therapeutics, Inc. (NRIX)

Role: General Counsel
Signature: /s/ Christine Ring
Stock symbol: NRIX
Transactions as of: Sep 10, 2021
Transactions value $: -$68,140
Form type: 4
Date filed: 9/13/2021, 04:07 PM
Previous filing: Sep 8, 2021
Next filing: Oct 12, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NRIX	Common Stock	Options Exercise	$3.72K	+2K	+155.52%	$1.86^*	3.29K	Sep 10, 2021	Direct	F1
transaction	NRIX	Common Stock	Sale	-$24.6K	-700	-21.3%	$35.10	2.59K	Sep 10, 2021	Direct	F1, F2
transaction	NRIX	Common Stock	Sale	-$17.9K	-500	-19.33%	$35.77	2.09K	Sep 10, 2021	Direct	F1, F3
transaction	NRIX	Common Stock	Sale	-$29.4K	-800	-38.35%	$36.76	1.29K	Sep 10, 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NRIX	Employee Stock Option (right to buy)	Options Exercise	$0	-2K	-1.86%	$0.00	106K	Sep 10, 2021	Common Stock	2K	$1.86	Direct	F1, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
F2	Represents the weighted average sale price. The lowest price at which shares were sold was $34.58 and the highest price at which shares were sold was $35.53. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
F3	Represents the weighted average sale price. The lowest price at which shares were sold was $35.64 and the highest price at which shares were sold was $35.90.
F4	The option vests as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares will vest monthly thereafter until the option is fully vested on August 9, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.